drugset / Trial / NCT05683886
A Study of KC1036 in Patients with Advanced Thymic Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
Timeline
- Start
- 2023-02-22
- Primary completion
- 2025-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KC1036 | Unknown | 60 mg | Oral |